Summit Therapeutics PLC

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

Quarter to June 2026, against a year earlier

16.13 1.94 +13.67%

Follow SMMT

Alert me

Summit Therapeutics PLC 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 4, 2026 · accepted 5:08 PM ET · Document on sec.gov · Filing index

Red flags

Short cash runway Nov 4, 2026
Summit Therapeutics PLC’s cash and short-term investments cover about 1.1 quarters of its operating cash burn

10-Q filed Nov 4, 2026 · The filing · sec.gov
Share dilution Nov 4, 2026
Shares outstanding rose 7.4% in a year, to 799.8 million

10-Q filed Nov 4, 2026 · The filing · sec.gov

Part II, Item 1A, Risk Factors, against the 10-Q filed Jul 23, 2026: no material changes, the filing says